Zobrazeno 1 - 10 of 44 pro vyhledávání: '"Dirk J. Richel"'
1
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Autor: George P. Kim, David Z. Chang, Daniel D. Von Hoff, Philip J. Stella, Berta Laquente, Karla Hurt, Tudor Ciuleanu, Cezary Szcylik, Jose A. Lopez-Martin, Scott M. Hynes, Aimee Bence Lin, Dirk J. Richel, Emiliano Calvo, Giovanni Luca Frassineti, Ji Lin, Donald A. Richards, Gerald Illerhaus, Stefano Cascinu
Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
BMC cancer, 17(1). BioMed Central
Recercat. Dipósit de la Recerca de Catalunya
instname
BMC Cancer
The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancreatic cancer. Patients with Stage II-IV lo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19a270d98056a450651be2deafc39661
http://hdl.handle.net/2445/124332
Zobrazit plný text záznamu
2
Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model
Autor: Carel J. M. van Noesel, Kun Shi, C. Arnold Spek, Karla C. S. Queiroz, Joris J. T. H. Roelofs, Dirk J. Richel
Publikováno v: The Journal of Pathology. 234:398-409
Protease-activated receptor-2 (PAR-2) is a G protein-coupled receptor that functions as a cell-surface sensor for coagulation factors and other proteases associated with the tumour microenvironment. Pancreatic cancer cells express high levels of PAR-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e7ffd3d996f6f67e1cf3b26ac28e031
https://doi.org/10.1002/path.4411
Zobrazit plný text záznamu
3
Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner
Autor: K. Shi, Karla C. S. Queiroz, Dirk J. Richel, J. Stap, C. A. Spek
Publikováno v: Journal of thrombosis and haemostasis, 11(10), 1892-1902. Wiley-Blackwell
Summary Background Protease-activated receptor 2 (PAR-2) is a G protein-coupled receptor suggested to play an important role in the proliferation and migration of tumor cells of epithelial origin. However, the role of PAR-2 in the setting of pancreat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf71c63a23e795a36077a5dd46f785fb
https://doi.org/10.1111/jth.12361
Zobrazit plný text záznamu
4
Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70
Autor: M. van Heijl, Jean H. G. Klinkenbijl, Johannes B. Reitsma, Johanna W. Wilmink, O.R.C. Busch, Dirk J. Richel, Jjghm Bergman, Maarten C.C.M. Hulshof, Rachel L. G. M. Blom, M. I. van Berge Henegouwen
Publikováno v: Diseases of the Esophagus. 26:510-516
Esophagectomy in elderly esophageal carcinoma patients is correlated with a high morbidity and even mortality. Studies on neoadjuvant chemoradiotherapy (NT) in elderly patients are scarce. The aim of this study was to evaluate the effect of advanced
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd355fc61ffe278da59ae1ecc401e8d9
https://doi.org/10.1111/j.1442-2050.2012.01394.x
Zobrazit plný text záznamu
5
Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer
Autor: J. J. B. van Lanschot, Dirk J. Richel, M. I. van Berge Henegouwen, M. van Heijl, Patrick M.M. Bossuyt, F. J. W. Ten Kate, B.M. Mearadji, Maarten C.C.M. Hulshof, Jaap Stoker, Saffire S.K.S. Phoa, Jjghm Bergman, Jikke M.T. Omloo, Gerrit W. Sloof
Publikováno v: European Journal of Surgical Oncology, 37(12), 1064-1071. W.B. Saunders
European journal of surgical oncology, 37(12), 1064-1071. W.B. Saunders Ltd
Background: Chemoradiotherapy is increasingly applied in patients with oesophageal cancer. The aim of the present study was to determine whether 3D-CT volumetry is able to differentiate between responding and non-responding oesophageal tumours early
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8ccdca9dfd4d9bdf209d972be7a5380
Zobrazit plný text záznamu
6
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Autor: Eric Van Cutsem, Hedy L. Kindler, Young Suk Park, Jaafar Bennouna, Harpreet Wasan, Gregory M Springett, Richard Letourneau, S. Ohkawa, Akihiro Funakoshi, Sinil Kim, Tatsuya Ioka, Alejandro D. Ricart, Dirk J. Richel, Peter C. Trask, Junji Furuse, Takuji Okusaka, Paul Bycott
Publikováno v: lancet oncology, 12(3), 256-262. Lancet Publishing Group
Summary Background Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. A randomised phase 2 trial of gemcitabine with or without axitinib in advanced pancreatic cancer suggested increased over
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a028873ad09fc4c403d4433c2b96785
https://doi.org/10.1016/s1470-2045(11)70004-3
Zobrazit plný text záznamu
8
Endogenous activated protein C is essential for immune-mediated cancer cell elimination from the circulation
Autor: Pieter Willem Kamphuisen, C. J. F. Van Noorden, H. R. Büller, Charles T. Esmon, Dirk J. Richel, G. L. Van Sluis, C. A. Spek, Lois W. Brüggemann
Publikováno v: Cancer letters, 306(1), 106-110. Elsevier Ireland Ltd
Fibrinogen and platelets play an important role in cancer cell survival in the circulation by protecting cancer cells from the immune system. Moreover, endogenous activated protein C (APC) limits cancer cell extravasation due to sphingosine-1-phospha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab530c7f3ec39540e5a4affd94d4d01c
https://doi.org/10.1016/j.canlet.2011.02.038
Zobrazit plný text záznamu
9
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
Autor: J.C. Reijneveld, M. E. van Linde, Dirk J. Richel, L. J. A. Stalpers, Cristina Lavini, Joost J.C. Verhoeff, Charles B. L. M. Majoie, W. R. van Furth
Publikováno v: Annals of oncology, 21(8), 1723-1727. Oxford University Press
Annals of Oncology, 21(8), 1723-1727. Oxford University Press
Verhoeff, J J C, Lavini, C, van Linde, M E, Stalpers, L J A, Majoie, C B L M, Reijneveld, J C, van Furth, W R & Richel, D J 2010, ' Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma ', Annals of Oncology, vol. 21, no. 8, pp. 1723-1727 . https://doi.org/10.1093/annonc/mdp591
Background Angiogenesis inhibition is a rational treatment strategy for high-grade glioma (HGG). Combined antiangiogenic therapy and chemotherapy could be beneficial, taking advantage of different mechanisms of antitumour activity of both therapies.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c18fd458eff2fbf867dfecdccffafd9
https://doi.org/10.1093/annonc/mdp591
Zobrazit plný text záznamu
10
Tumor microvasculature supports proliferation and expansion of glioma-propagating cells
Autor: Jan Paul Medema, Joost J.C. Verhoeff, Martin R. Sprick, Rosemarie ten Cate, Wouter R. van Furth, Tijana Borovski, Nienke A. de Vries, Kate Cameron, Olaf van Tellingen, Dirk J. Richel
Publikováno v: International journal of cancer. Journal international du cancer, 125(5), 1222-1230. Wiley-Liss Inc.
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. The identification of 'cancer stem cells' (CSC) has shed new light on the potential mechanism of therapy resistance of these tumors. Because these cells appear to be
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f52a44508888b35b9ca8ff612388507d
https://doi.org/10.1002/ijc.24408
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje